Table 1.
A summary of active and completed clinical trials studying curcumin in cancer treatment and prevention.
| Official Title of Study | Disease | Number of Patients | Institution | Phase | Study Design | Administration and Dosage of Curcumin | Start | ClinicalTrials.gov Identifier: | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Avastin/FOLFIRI in Combination with Curcumin in Colorectal Cancer Patients with Unresectable Metastasis | Colorectal Cancer | 50 | Gachon University Gil Medical Center | Phase 2 | Bevacizumab/FOLFIRI in Combination with Curcumin | Oral, 100 mg | August, 2015 | NCT02439385 |
| 2 | Curcumin Chemoprevention of Colorectal Neoplasia | Colorectal Cancer | 40 | University of North Carolina, Chapel Hill | Phase 1 | Curcumin | Oral, 4000 mg | November 2010 | NCT01333917 |
| 3 | A Pilot, Feasibility Study of Curcumin in Combination with 5FU for Patients with 5FU-Resistant Metastatic Colon Cancer | Colorectal Cancer | 13 | Baylor Charles A. Sammons Cancer Center | Phase 1 | CurcuminIn Combination with 5-Flurorouracil | Oral, 500 mg | March 2016 | NCT02724202 |
| 4 | A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients | Colorectal Cancer | 23 | University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center | Phase 1 | Curcumin + Irinotecan | Oral, 4000 mg, | June 2013 | NCT01859858 |
| 5 | A Randomized Double Blinded Study of Curcumin with Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer | Colorectal Cancer | 45 | M.D. Anderson Cancer Center | Phase 2 | Capecitabine + Curcumin vs. Capecitabine + placebo | - | August 2008 | NCT00745134 |
| 6 | A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) with Standard Care FOLFOX Chemotherapy in Patients with Inoperable Colorectal Cancer. | Colorectal Cancer | 41 | Dept Oncology, Leicester Royal Infirmary, University Hospitals Leicester | Phase 2 | Curcumin + Chemotherapy—FOLFOX | Oral, 2000 mg | February 2012 | NCT01490996 |
| 7 | Meriva for Treatment-Induced Inflammation and Fatigue in Women with Breast Cancer | Breast Cancer | 30 | Emory Winship Cancer Institute | Phase 2 | Curcumin vs. Placebo | Oral, 100 mg | May 2015 | NCT01740323 |
| 8 | Effect of Preoperative Curcumin in Breast Cancer Patients | Breast Cancer | 30 | University of Malaya | N/A | Curcumin vs. Placebo | Oral, 8000 mg | June 2017 | NCT03847623 |
| 9 | Study of Efficacy of Curcumin in Combination with Chemotherapy in Patients with Advanced Breast Cancer: Randomized, Double Blind, Placebo Controlled Clinical Trial | Breast Cancer | 150 | National Center of Oncology, Armenia | Phase 2 | Curcumin + Paclitaxel vs. Paclitaxel + Placebo | Parenteral, 300 mg | March, 2017 | NCT03072992 |
| 10 | Nanoemulsion Curcumin for Obesity, Inflammation, and Breast Cancer Prevention—A Pilot Trial | Breast Cancer | 29 | Ohio State University Comprehensive Cancer Center | N/A | Curcumin | Oral, 100 mg | June 2013 | NCT01975363 |
| 11 | Radiation Therapy with or without Curcumin Supplement in Treating Patients with Prostate Cancer | Prostate Cancer | 40 | Oncology and Radiotherapy Department, Besat Hospital, Tehran | N/A | Curcumin vs. Placebo | Oral, 3000 mg | March 2011 | NCT01917890 |
| 12 | Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer | Prostate Cancer | 50 | M.D. Anderson Cancer Center | Phase 2 | Curcumin | Oral, 8000 mg | November 2004 | NCT00094445 |
| 13 | Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer | Prostate Cancer | 64 | Shahid Beheshti University of Medical Sciences | Phase 2 | Curcumin vs. Placebo | Oral, 120 mg | March 2016 | NCT02724618 |
| 14 | Phase II Trial of Gemcitabine and Curcumin in Patients with Advanced Pancreatic Cancer | Pancreatic Cancer | 17 | Rambam Health Care Campus | Phase 2 | Curcumin + Gemcitabine | Oral, 8000 mg | July 2004 | NCT00192842 |
| 15 | An Exploratory Biomarker Trial of the Food Substances Curcumin C3 Complex in Subjects with Newly Diagnosed Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | 33 | Feist-Weiller Cancer Center at Louisiana State University Health SciencesNational Cancer Institute (NCI) | Phase 1 | Curcumin | Oral, 8000 mg | June 2010 | NCT01160302 |
| 16 | Effect of Curcumin Addition to Standard Treatment on Tumor-Induced Inflammation in Endometrial Carcinoma | Endometrial Carcinoma | 7 | University Hospital KU Leuven Campus Gasthuisberg | Phase 2 | Curcumin | Oral, 2000 mg | October 2013 | NCT02017353 |
| 17 | Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis | Chronic Atrophic Gastritis/Gastric Cancer | 100 | National Cancer Institute (NCI), Mayo Clinic in Rochester | Phase 2 | Curcumin vs. Placebo | Oral, 200 mg | April 2017 | NCT02782949 |
| 18 | Pilot Study of Curcumin (Diferuloylmethane Derivative) with or without Bioperine in Patients with Multiple Myeloma | Multiple Myeloma | 42 | M.D. Anderson Cancer Center | N/A | Curcumin vs. Curcumin + Bioperine | Oral, 2000 mg | November 2004 | NCT00113841 |